The antihyperglycaemic effect of metf ormin therapeutic and cellular mechanisms

Drugs

Volumn 58, Issue SUPPL. 1, 1999, Pages 31-39

  Wiernsperger, Nicolas F ^a,b   Bailey, Clifford J ^b  

^a MERCK KGAA   (Germany)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCAGON; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER; GLYCOGEN; GLYCOGEN SYNTHASE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PROTEIN TYROSINE KINASE; TRIACYLGLYCEROL;

CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCOGENOLYSIS; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN SENSITIVITY; MEMBRANE FLUIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; GLUCONEOGENESIS; GLYCOGEN SYNTHASE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; RECEPTOR, INSULIN;

EID: 0032697674     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958001-00009     Document Type: Article

References (62)

1. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72
2. Bailey CJ, Turner RC. Drug therapy: metformin. N Engl J Med 1996; 334:574-9
3. Campbell IW, Hewlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: a metaanalysis. Diabetes Metab Rev 1995; II: S57-62
4. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-depcndent diabetes mellitus. N Enel J Med 1995:333:541-8
5. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58
6. Bailey CJ. Metformin - an update. Gen Pharmacol 1993; 24: 1299-1309
7. Wiernsperger NF. Preclinical pharmacology of biguanides. Handbook of Experimental Pharmacology 1996; 119: 305-58
8. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacofcinet 1996:30:359-71
9. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994; 24: 4957
10. Cook DE, Blair JB, Gilfillan C, et al. Mode of action of hypoglycaemic agents. IV. Control of the hypoglycaemic activity of phenethylbiguanide in rats and guinea pias. Biochem Pharmacol 1973; 22: 2121-8
11. Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. Biochem Pharmacol 1988; 37: 4353-8
12. Wollen N, Bailey CJ. Melformin potentiates the antigluconeosenic action of insulin. Diabete Metab 1988; 14:88-91
13. Yu B, Pugazhenthi S, Khandelwal RL. Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes. Biochem Pharmacol 1994; 48: 949-4
14. Alengrin F, Grossi G, Canivet B, et al. Inhibitory effects of metformin on insulin and glucagon action in rat hepatocytes involve post-receptor alterations. Diabète Metab 1987; 13: 591-7
15. Radziuk J, Zhang Z, Wiernsperger N, et al. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 1997; 46: 1406-13
16. Komori T, Hotta N, Kobayastic M, et al. Biguanides may produce hypoglycémie action in isolated rat hepatocytes through their effects on L-alanine transport. Diabetes Res Clin Pract 1993; 22: 11-7
17. Argaud D, Roth H, Wiernsperger N, et al. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur }Biochem 1993; 213: 1341-8
18. Reddi AS, Jyothirmayi ON. Effect of chronic metformin treatment on hepatic and muscle glycogen metabolism in KK mice. Biochem Med Metab Biol 1992; 47: 124-32
19. Christiansen MP, Linfoot PA, Neese RA, et al. Metformin: effects upon postabsorptive intrahepatic carbohydrate fluxes [abstract 937]. Diabetes 1997; 46 Suppl. I: 244
20. Gawler D, Milligan G, Houslay MD. Treatment of streptozotocin-diabetic rats with metformin restores the ability of insulin to inhibit adenylate cyclase activity and demonstrates that insulin does not exert this action through the inhibitory guanine nucleotide regulatory protein Gi. Biochem J 1988; 249: 537-42
21. Gawler DJ, Wilson A, Houslay MD. Metformin treatment of lean and obese Zucker rats modulates the ability of glucagon and insulin to regulate hepatocyte adenylate cyclase activity. JEndocrinol 1989; 122:207-12
22. Melin B, Cherqui G, Blivet MJ, et al. Dual effect of metformin in cultured rat hepatocytes: potentiation of insulin action and prevention of insulin-induced resistance. Metabolism 1990; 39: 1089-95
23. Minassian C, Tarpin S, Mithieux G. Role of glucose-6-phosphatase, glucokinase and glucose-6-phosphate in liver insulin resistance and its correction by metformin. Biochem Pharmacol 1998; 55: 1213-19
24. Saleh SI, Abdel Khaled A, Sharaf AA, et al. Studies of the effect of oral hypoglycaemic agents on hepatic glycogenolysis. Pharmacol Res Commun 1974; 6: 539-50
25. Pears JS, Jung RT, Burchell A. Contrasting effects of metformin on glucose-6-phosphatase from fed and diabetic livers [abstract]. Diabetic Med 1990; 7 Suppl. 2: 12
26. Rossetti L, DeFronzo RA, Ciherzi R, et al. Effect of metformin treatment on insulin action in diabetic rats: in vivo and m yilro correlations. Metabolism 1990; 39:425-35
27. Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol 1994; 112:671-5
28. Bailey CJ, Puah JA. Effect of metformin on glucose metabolism in mouse soleus muscle. Diabetes Metab 1986; 12: 212-8
29. Damsbo P, Handbery A, Beck-Nielsen H. Reversibility of the defect in glycogen synthase activity in skeletal muscle from obese NIDDs treated with diet and metformin [abstract 1070]. Diabetes 1990; 39 Suppl. 1:277
30. Galuska G, Zierath JR, Thorne A, et al. Melformin increases insulin-stimulated glucose transport in insulin resistant human skeletal muscle. Diabetes Metab 1991; 17: 59-63
31. Galuska G, Nolle LA, Zierath JR, et al. Effect of metformin on insulin-stimulated glucose Iransport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 1994; 37: 826-32
32. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of melformin action in obese and lean non-insulin dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301
33. Sarabia V, Lam L, Burdelte E, et al. Glucose transport in human skeletal muscle cells in culture: stimulation by insulin and metformin. J Clin Invest 1992; 90: 1386-95
34. Muntoni S. Inhibition of fatty acid oxidation by biguanides: implications for metabolic physiopathology. Adv Lipid Res 1974; 12:311-77
35. Corsini GU, Sirigu F, Tagliamonte P, et al. Effects of biguanides on fatty acid and glucose oxidation in muscle. Pharmacol Res Commun 1974; 6: 253-61.
36. Riccio A, Del Prato S, Vigili de Kreutzenberg S, et al. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of melformin. Diabetes Metab 1991; 17Suppl. I: 180-4
37. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994:43:920-8
38. Zavaroni I, Dall Aglio E, Bruschi F, et al. Inhibition of carbohydrate-induced hypertriglyceridemia by metformin. Horm Metab Res 1984; 16:85-7
39. Jeppesen J, Zhou MY, Chen YD, et al. Effect of melformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994; 17: 1093-9
40. Storlien L, Baur LA, Kirketos AD, et al. Dietary fats and insulin action. Diabetologia 1996; 39: 621-31
41. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10
42. Penicaud L, Hitier Y, Ferre P, et al. Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J 1989; 262: 881-5
43. Bailey CJ, Wilcock C, Day C. Effect of melformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 1992; 105: 1009-13
44. Yoa RG, Rapin JR, Wiernsperger NF, et al. Demonstration of defective glucose uptake and storage in erythrocytes from non-insulin dependent diabetic patients and effects of metformin. Clin Exp Pharmacol Physiol 1993; 20: 563-7
45. Matthaei S, Hamman A, Klein HH, el al. Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipoctes. Diabetes 1991; 40: 850-7
46. Kozka IJ, Holman CD. Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes 1993; 42: 1159-65
47. Handal HS, Ramlal T, Reyes R, et al. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 1992; 131: 1165-73
48. Matthaei S, Reibold JP, Hamann A, et al. In vivo melformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased func-tional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology 1993; 133: 304-11
49. SassonS.GorowitsN, JoostHG.etal. Regulation by metformin of the hexose transport system in vascular endothelium and smooth muscle cells. BrJ Pharmacol 1996; 117: 1318-24
50. Thomas CR, Turner SL, Jefferson WH, et al. Prevention of dexamelhasone-induced insulin resistance by metformin. Biochem Pharmacol 1998; 56: 1145-50
51. Hothcr-Nielsen O, Schmilz O, Andersen PH, et al. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol 1989; 120: 257-65
52. Detaille D, Wiernsperger N, Devos P. Potentiating effect of metformin on insulin-induced glucose uptake and glycogen metabolism within Xenopus oocytes. Diabetologia 1998; 41: 2-8
53. Estrada DE, Elliott E, Zinman B, et al. Regulation of glucose transport and expression of GLUT3 transporters in human circulating mononuclear cells: studies in cells from insulindependent diabetic and nondiabelic individuals. Metabolism 1994; 43: 591-8
54. Wiernsperger N, Rapin JR. Metformin-insulin interactions: from organ to cell. Diabetes Metab Rev 1995; 11 Suppl. 1: S3-12
55. Stith B J, Goalstone M L, Espinoza R, et al. The antidiabetic drug melformin elevates receptor tyrosine kinase activity and inositol 1,4,5-triphosphate mass in Xenopus oocytes. Endocrinology 1996; 197: 2990-9
56. Santos RF, Nomizo R, Wajchenberg BL, et al. Changes in insulin receptor tyrosine kinase activity associated with metformin treatment of type 2 diabetes. Diabetes Metab 1995; 21: 274-80
57. Grigorescu F, Baccara MT, Rouard M, et al. Insulin and IGF-1 signaling in oocyte maturation. Horm Res 1994; 42: 55-61
58. Zaibi MS, Padieu P, Chessebeuf Padieu M, et al. Metformin induces an agonist-specific increase in albumin production by primary cultured rat hepatocytes. Biochem Pharmacol 1995; 50: 775-80
59. Grigoreseu F, Poucheret P, Bouix O, et al. Metformin potentiates phosphatidylinositol-3 kinase by IRS-2 recruitment in rat hepatic tissue [abstract]. Diabetologia 1998; 41 Suppl. 1: A189
60. Meuillet B, Wiernsperger NF, Hubert P, et al. Biguanide effects on insulin signalling. Ann NY Acad Sei 1997; 827:546-9
61. NakamuraS, Thirone A, CarvalhoC, etal. Effect of metformin on early steps of insulin signal transduction in liver and muscle of aging rats [abslractjroiabetes 1998; 47 Suppl. 1: A296
62. Freisleben HJ, Ruckert S, Wiernsperger N, et al. The effects of glucose, insulin and metformin on the order parameters of isolated red cell membranes. Biochem Pharmacol 1992; 43: 1185-9